[{"indications": "Indications\u00a0Parkinson\u2019s disease; endocrine disorders\r\n(section 6.7.1)", "name": "BROMOCRIPTINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Dopamine-receptor agonists", "BROMOCRIPTINE"], "cautions": "Cautions\u00a0see Bromocriptine in section 6.7.1 and notes above", "side-effects": "Side-effects\u00a0\n(From Dopamine-receptor agonists: British National Formulary)\nDopamine-receptor agonists and Bromocriptine, %s\n(From BROMOCRIPTINE: British National Formulary)\nSide-effects\u00a0see notes above; also nasal congestion; less commonly vomiting, postural hypotension, fatigue, dizziness, dry mouth; also, particularly with high doses, confusion, psychomotor excitation, hallucinations; rarely diarrhoea, gastro-intestinal bleeding, gastric ulcer, abdominal pain, tachycardia, bradycardia, arrhythmia, insomnia, psychosis, visual disturbances, tinnitus; very rarely vasospasm of fingers and toes particularly in patients with Raynaud\u2019s syndrome, and effects like neuroleptic malignant syndrome on withdrawal; urinary incontinence, leucopenia, thrombocytopenia, hyponatraemia, reversible hearing loss, increased libido, and hypersexuality also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106288.htm", "doses": ["First week 1\u20131.25\u00a0mg at night, second week 2\u20132.5\u00a0mg at\r\nnight, third week 2.5\u00a0mg twice daily, fourth week 2.5\u00a0mg 3 times daily\r\nthen increasing by 2.5\u00a0mg every 3\u201314 days according to response to\r\na usual range of 10\u201330\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0see Bromocriptine, section 6.7.1"}, {"indications": "Indications\u00a0Parkinson\u2019s disease; endocrine disorders\r\n(section 6.7.1)", "name": "BROMOCRIPTINE - DOPAMINE-RECEPTOR AGONISTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Dopamine-receptor agonists", "BROMOCRIPTINE"], "cautions": "Cautions\u00a0see Bromocriptine in section 6.7.1 and notes above", "side-effects": "Side-effects\u00a0\n(From Dopamine-receptor agonists: British National Formulary)\nDopamine-receptor agonists and Bromocriptine, %s\n(From BROMOCRIPTINE: British National Formulary)\nSide-effects\u00a0see notes above; also nasal congestion; less commonly vomiting, postural hypotension, fatigue, dizziness, dry mouth; also, particularly with high doses, confusion, psychomotor excitation, hallucinations; rarely diarrhoea, gastro-intestinal bleeding, gastric ulcer, abdominal pain, tachycardia, bradycardia, arrhythmia, insomnia, psychosis, visual disturbances, tinnitus; very rarely vasospasm of fingers and toes particularly in patients with Raynaud\u2019s syndrome, and effects like neuroleptic malignant syndrome on withdrawal; urinary incontinence, leucopenia, thrombocytopenia, hyponatraemia, reversible hearing loss, increased libido, and hypersexuality also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106288.htm", "doses": ["First week 1\u20131.25\u00a0mg at night, second week 2\u20132.5\u00a0mg at\r\nnight, third week 2.5\u00a0mg twice daily, fourth week 2.5\u00a0mg 3 times daily\r\nthen increasing by 2.5\u00a0mg every 3\u201314 days according to response to\r\na usual range of 10\u201330\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0see Bromocriptine, section 6.7.1"}, {"indications": "Indications\u00a0see notes above\r\nand under Dose; Parkinson\u2019s disease (%s\n(From 4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease: British National Formulary)\n4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease)", "name": "BROMOCRIPTINE - BROMOCRIPTINE AND OTHER DOPAMINERGIC DRUGS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.1 Bromocriptine and other dopaminergic drugs", "BROMOCRIPTINE"], "cautions": "Cautions\u00a0\n(From 6.7.1 Bromocriptine and other dopaminergic drugs: British National Formulary)\nCautions\u00a0see notes below; also bromocriptine and cabergoline should be used with caution in patients with a history of peptic ulcer, particularly in acromegalic patients. Treatment should be withdrawn if gastro-intestinal bleeding occurs. In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment). Bromocriptine and cabergoline should be used with caution in patients with Raynaud\u2019s syndrome and cardiovascular disease (see also Contra-indications under Bromocriptine, below). Monitor for fibrotic disease (see Fibrotic Reactions, below). Caution is also advised in patients with a history of serious mental disorders (especially psychotic disorders) and in those with acute porpyhria (see section 9.8.2). Tolerance may be reduced by alcohol.; also specialist evaluation\u2014monitor\r\nfor pituitary enlargement, particularly during pregnancy; monitor visual field to detect secondary field loss\r\nin macroprolactinoma; contraceptive advice\r\nif appropriate (oral contraceptives may increase prolactin concentration); interactions: Appendix 1 (bromocriptine)", "side-effects": "Side-effects\u00a0\n(From 6.7.1 Bromocriptine and other dopaminergic drugs: British National Formulary)\nSide-effects\u00a0Nausea, constipation, and headache are common side-effects of bromocriptine and cabergoline. Paraesthesia has been reported rarely. Other reported side-effects include hypotension (see also Hypotensive Reactions, below), drowsiness (see also Driving, below), dyskinesia, pathological gambling, increased libido, hypersexuality, leg cramps, allergic skin reactions, alopecia, and peripheral oedema. Bromocriptine and cabergoline have been associated with pleuritis, pleural effusion, cardiac valvulopathy, pericardial effusion, constrictive pericarditis, and retroperitoneal, pleural, and pulmonary fibrosis (see Fibrotic Reactions). ; also\r\nnasal congestion; less commonly vomiting, postural\r\nhypotension, fatigue, dizziness, dry mouth; also, particularly with high doses, confusion, psychomotor excitation, hallucinations; rarely diarrhoea, gastro-intestinal bleeding, gastric ulcer,\r\nabdominal pain, tachycardia, bradycardia, arrhythmia, insomnia, psychosis,\r\nvisual disturbances, tinnitus; very rarely vasospasm\r\nof fingers and toes particularly in patients with Raynaud\u2019s syndrome,\r\nand effects like neuroleptic malignant syndrome on withdrawal; urinary\r\nincontinence, leucopenia, thrombocytopenia, hyponatraemia, reversible\r\nhearing loss, increased libido, and hypersexuality also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4461.htm", "doses": ["Prevention or suppression of lactation (but see notes\r\nabove and under Cautions), 2.5\u00a0mg on day 1 (prevention) or daily for\r\n2\u20133 days (suppression); then 2.5\u00a0mg twice daily for 14 days", "Hypogonadism,\r\ngalactorrhoea, infertility, initially 1\u20131.25\u00a0mg at bedtime, increased\r\ngradually; usual dose 7.5\u00a0mg daily in divided doses, increased if\r\nnecessary to max. 30\u00a0mg daily, usual dose in infertility without hyperprolactinaemia,\r\n2.5\u00a0mg twice daily", "Acromegaly, initially 1\u20131.25\u00a0mg at bedtime, increase gradually\r\nto 5\u00a0mg every 6 hours", "Prolactinoma, initially 1\u20131.25\u00a0mg at bedtime; increased gradually\r\nto 5\u00a0mg every 6 hours (occasional patients may require up to 30\u00a0mg\r\ndaily)", "child under 15 years, not recommended"], "pregnancy": "Pregnancy\u00a0see Cautions above"}]